Improvement of coronary flow reserve after long-term therapy with enalapril

Hypertension

Volumn 27, Issue 5, 1996, Pages 1031-1038

  Motz, Wolfgang ^a   Strauer, Bodo E ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

angina pectoris; angiotensin converting enzyme inhibitors; coronary circulation; enalapril; hypertrophy, left ventricular

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL;

ADULT; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; MICROVASCULATURE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029876289     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.5.1031     Document Type: Article

References (43)

1. Pichard AD, Frolin R, Smith H, Ambrose J, Meller J, Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type: evidence for an impaired coronary vascular reserve. Am J Cardiol. 1981;47:547-554.
2. Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol. 1979;44:999-1006.
3. Marcus ML, Doty DB, Hiratzka LF, Wright CB, Eastham CL. Decreased coronary reserve: a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med. 1982;367:1362-1366.
4. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
5. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac flbroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
6. Cruickshank JM. Reversibility of left ventricular hypertrophy (LVH) by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
7. Motz W, Strauer BE. Rückbildung der hypertensiven Herzhypertrophie durch chronische Angiotensin-Konversions-EnzymHemmung. Z Kardiol. 1988;77:53-60.
8. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044-1049.
9. Sen S, Tarazi RC, Bumpus FM. Reversal of cardiac hypertrophy in renal hypertensive rats: medical vs. surgical therapy. Am J Physiol. 1981;270:H408-H412.
10. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
11. Eberli FR, Ritter M, Schwitter J, Bortone A, Schneider J, Hess OM, Krayenbühl HP. Coronary reserve in patients with aortic valve disease before and after successful aortic valve replacement. Eur Heart J. 1991;12:127-138.
12. Sahn DJ, De Maria A, Kisslo J, Weymann A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58: 1072-1086.
13. Bretschneider HJ, Cott L, Hilgert G, Probst R, Rau G. Gaschromatographische Trennung und Analyse von Argon als Basis einer neuen Fremdgasmethode zur Durchflußmessung von Organen. Verh Disch Ges Kreisauforsch. 1966;32:267-273.
14. Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol. 1991;68:996-1003.
15. Schlant RC, Blomqvist CG, Brandenburg RO, De Busk R, Ellestad MH, Fletcher OF, Froelicher VF, Hall RJ, McCallister BD, McHenry PL, Ryan TJ, Sheffield LT. Guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Exercise Testing). J Am Coll Cardiol. 1986;8:725-732.
16. Campeau L. Grading of angina pectoris. Circulation. 1975;54: 522-530.
17. Zöfel P. Statistik in der Praxis. Stuttgart, FRG: Gustav Fischer; 1985:236-242.
18. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol. 1990;15:775-783.
19. Mall G, Greber D, Gharebhagi H, Wiest G, Mattfeldt T, Ganten U. Myokardprotektion und Hypertrophieregression bei spontan hypertensiven Ratten durch Nifedipin und Moxonidin. Stereologische Untersuchungen. In: Ganten D, Mall G, eds. Herz-Kreislauf-Regulation, Organprotektion und Organschaden, Stuttgart, FRG: Schattauer; 1991:91-106.
20. Turek Z, Kubat K, Kazda S, Hoofd V, Rahnsan K. Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine. Cardiovasc Res. 1987;21:725-729.
21. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Plhysiol. 1989;257:H1110-H1118.
22. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 1992;20:175-180.
23. Keely FW, Elmoselhi A, Leenen FHH. Enalapril suppresses normal collagen accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol. 1992;62:H1013-H1021.
24. Motz W, Schwartzkopff B, Vogt M. Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Eur Heart J. 1995;16(suppl C):69-73.
25. Laks MN. Norepinephrine: the myocardial hypertrophy hormone? Am Heart J. 1976;91:674-675.
26. Östman-Smith I. Cardiac sympathetic nerves as the final common pathway of adaptive cardiac hypertrophy. Clin Sci. 1981;61:265-272.
27. Tarazi RC, Sen S, Saragoca M, Kairallah P. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J. 1982;3(suppl A):A103-A110.
28. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
29. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin If in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1419-1424.
30. Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, Dzau VJ. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension. 1989;13:706-711.
31. Lindpaintiier K, Jin M, Wilhelm MJ, Suzuki F, Linz W, Schoelkens BA, Ganten D. Intracardiac generation of angiotensin and its physiologic role. Circulation. 1988;77(suppl I):I-18-I-23.
32. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest. 1990;86:1913-1920.
33. Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol. 1988;62:161-163.
34. Weber KT, Anversa P, Armstrong PW, Brilia CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz W, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
35. Magrini F, Reggiani R, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med. 1988;84(suppl 3A): 55-60.
36. Michel J-B, Levy BI. Vascular effects of ACE inhibition by perindopril. Drugs. 1990;39(suppl 1):39-42.
37. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989;7:267-275.
38. Levy IB, Michel JB, Salzmann JL, Azizi M, Poitevin P, Safar M, Camilleri JP. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res. 1988;63:227-239.
39. Wiemer G, Schoelkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endotheiium-derived bradykinin. Hypertension. 1991;18:558-563.
40. Anderson PG, Bishop SP, Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res. 1989;64:1127-1136.
41. Brush JE Jr, Cannon RO III, Schenke WH, Bonow RO, Leon MB, Maron BJ, Epstein SE. Angina due to microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319:1302-1307.
42. Motz W, Vogt M, Scheler S, Schwartzkopff B, Strauer BE. Verbesserung der Koronarreserve nach Hypertrophieregression durch blutdrucksenkende Therapie mit einem β-Rezeptorenblocker. Deutsch Med Wschr. 1993;118:535-540.
43. Rossen JD, Quillen JE, Lopez AG, Sternberg RG, Talman GL, Winniford MD. Comparison of coronary vasodilation with intranenous dipyridamole and adenosine. J Am Coll Cardiol. 1991; 18:485-491.